Opus Genetics
IRD
31 hedge funds and large institutions have $5.71M invested in Opus Genetics in 2014 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 7 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
11% less funds holding
Funds holding: 35 → 31 (-4)
13% less capital invested
Capital invested by funds: $6.57M → $5.71M (-$853K)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$399K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$151K |
| 3 |
Goldman Sachs
New York
|
+$72.4K |
| 4 |
CCM
Condor Capital Management
Martinsville,
New Jersey
|
+$47.5K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$45K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.07M |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$63K |
| 3 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$34.9K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$32.1K |
| 5 |
OC
Oppenheimer & Co
New York
|
-$23K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Citigroup
New York
| $6K | -$4.32K | -12 | -44% |
|
27
Canada Life
Winnipeg,
Manitoba, Canada
| $5K | – | – | – |
|
|
TRCT
28
Tower Research Capital (TRC)
New York
| $3K | -$720 | -2 | -20% |
|
29
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | -$720 | -2 | -50% |
|
30
Ameriprise
Minneapolis,
Minnesota
| $1K | – | – | – |
|
|
CP
31
Corbenic Partners
Bethlehem,
Pennsylvania
| $1K | – | – | – |
|
|
32
Morgan Stanley
New York
| – | -$1.07M | -2,575 | Closed |
|
|
OC
33
Oppenheimer & Co
New York
| – | -$23K | -56 | Closed |
|
|
U
34
UBS
Zurich,
Switzerland
| – | -$17K | -40 | Closed |
|
35
Two Sigma Investments
New York
| – | -$16K | -39 | Closed |
|
|
FNYS
36
First New York Securities
New York
| – | -$13.1K | -31 | Closed |
|
|
CS
37
Credit Suisse
Zurich,
Switzerland
| – | -$10K | -24 | Closed |
|
38
Fisher Asset Management
Camas,
Washington
| – | -$9K | -21 | Closed |
|
IRD Hedge Fund Activity: Q3 2014 in Review
31 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q3 2014, worth a combined $5.71M — down 13% from $6.57M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of IRD and 3 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 8 added.
The largest buyer was Vanguard Group, adding an estimated $399K. The largest seller was Morgan Stanley, exiting entirely with an estimated $1.07M sold.
- 31 institutional investors held Opus Genetics (IRD) as of Q3 2014, down from 35 in Q2 2014.
- Funds reported $5.71M of Opus Genetics stock for Q3 2014, down 13% quarter-over-quarter.
- 3 funds opened new Opus Genetics positions in Q3 2014 and 7 closed out, a net change of -4 holders.
- The largest Opus Genetics buyer in Q3 2014 was Vanguard Group, an estimated $399K added.
- The largest Opus Genetics seller in Q3 2014 was Morgan Stanley, an estimated $1.07M sold.
Based on aggregated 13F filings for Q3 2014.